膀胱癌风险评估(COBRA)评分在TCGA膀胱癌队列中的验证
本研究在TCGA膀胱癌队列(n=412,分析队列n=273)中验证COBRA评分对根治性膀胱切除术后总生存的预测价值,并探索其在不同分子亚型中的效用。中位随访18个月,COBRA评分每增加1分与死亡风险显著增加相关(多因素HR=1.54,95%CI 1.32-1.79),且在基底型、管腔浸润型和管腔乳头型亚型中均保持独立预后价值。
要点
- COBRA评分在TCGA队列中验证可预测根治性膀胱切除术后总生存。
- 评分每增加1分,多因素死亡风险增加54%(HR=1.54)。
- 在基底型、管腔浸润型和管腔乳头型分子亚型中评分仍具预后价值。
核心结论
- COBRA评分在TCGA膀胱癌队列中得到验证,可用于根治性膀胱切除术后风险分层。
- 结合分子亚型信息,COBRA评分有助于早期识别辅助治疗和临床试验的候选者。
研究设计与样本
- 回顾性分析TCGA膀胱癌队列(n=412),复习根治性膀胱切除病理报告计算COBRA评分。
- 分析队列n=273,中位随访18个月,采用Kaplan-Meier曲线及单因素/多因素Cox比例风险模型评估总生存。
主要发现
- COBRA评分每增加1分与死亡风险显著增加相关:单因素HR=1.52(95%CI 1.32-1.75),多因素HR=1.54(95%CI 1.32-1.79)。
- 按分子亚型分层多因素模型中,基底型HR=1.37(95%CI 1.07-1.74),管腔浸润型HR=1.70(95%CI 1.10-2.64),管腔乳头型HR=1.62(95%CI 1.28-2.06)。
临床怎么用
- 根治性膀胱切除术后可使用COBRA评分辅助风险分层,结合分子亚型信息指导辅助治疗决策和临床试验筛选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the Cancer of the Bladder Risk Assessment (COBRA) score in The Cancer Genome Atlas (TCGA) bladder cancer cohort. Second, to investigate the utility of the COBRA score within each bladder cancer molecular subtype following radical cystectomy (RC) and determine if it can help identify candidates for adjuvant therapies and clinical trials. METHODS: Among the TCGA bladder cancer cohort (n = 412), RC pathology reports were reviewed to calculate COBRA scores. Kaplan-Meier survival curves along with univariable and multivariable Cox proportional hazard models were used to determine the clinical utility of the COBRA score to predict overall survival (OS) within the overall cohort and within each molecular subtype (if n>30 within subtype). RESULTS: In the analytic cohort (n = 273) there was a median follow-up of 18 months. Higher COBRA score was associated with significant increased risk of death in both univariable (HR = 1.52 per point [PP] 95% CI [1.32, 1.75)] and multivariable models (HR = 1.54 PP 95% CI [1.32, 1.79]). This remained true in multivariable models stratified by molecular subtype for basal (HR = 1.37 PP 95% CI [1.07, 1.74]), luminal infiltrated (HR = 1.70 PP 95% CI [1.10, 2.64]), and luminal papillary (HR = 1.62 PP 95% CI [1.28, 2.06]) tumors. CONCLUSION: Our findings validate the COBRA score in the TCGA bladder cancer cohort. This suggests the COBRA score can be used in conjunction with molecular subtyping information to help guide clinical decision-making following RC to improve risk stratification and allow for earlier identification of candidates for adjuvant therapies and clinical trials.
引用
- Chappidi MR, Welty C, Choi W, et al. Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. Urology. 2021. PMID: 34118229. doi:10.1016/j.urology.2021.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。